Concert Pharmaceuticals, Inc. (CNCE) Names Thomas Auchincloss To Board Of Directors And Chair Of The Audit Committee

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Thomas G. Auchincloss, Jr. will join its Board of Directors and serve as the independent chair of the Board's Audit Committee, effective immediately. Mr. Auchincloss replaces Helmut Schühsler as Chair of the Audit Committee. Dr. Schühsler will remain a member of Concert's Board of Directors.

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.